April 11, 2022
April 11, 2022 – Xigduo® XR (dapagliflozin/metformin) has received a new indication for one of its active pharmaceutical ingredients (APIs), dapagliflozin, to reduce the risk of
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Global Reach Health News
April 8, 2022
April 8, 2022 – ArmonAir® Digihaler® (fluticasone propionate) has received an expanded indication to
provide maintenance treatment (as prophylactic therapy) for asthma in patients
April 6, 2022
April 6, 2022 – Novartis has obtained FDA approval for Vijoice® (alpelisib) to treat severe manifestations
of PIK3CA-related overgrowth spectrum (PROS) in patients at least two years of age
April 6, 2022
April 6, 2022 – IgalmiTM (dexmedetomidine) sublingual film, made by BioXcel Therapeutics, has received FDA approval to treat agitation associated with schizophrenia
April 1, 2022
April 1, 2022 – Gilead’s Yescarta® (axicabtagene ciloleucel) has been approved to treat adults diagnosed
with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy
April 1, 2022
April 1, 2022 – ViiV Healthcare’s Triumeq PD® (abacavir/dolutegravir/lamivudine) has been approved to
treat HIV-1 infection in children who weigh 10kg (22 pounds) to less than 25kg (55 pounds)
March 30, 2022
March 30, 2022 – Janssen’s Edurant® (rilpivirine) and ViiV Healthcare’s Vocabria® (cabotegravir) have
received expanded indications for the short-term treatment of HIV-1 infection
March 30, 2022
March 30, 2022 – The FDA has approved updated prescribing information for Cabenuva® (cabotegravir and rilpivirine), ViiV Healthcare’s long-lasting injectable HIV treatment